Table 1.
Mass drug administration and fMDA household testing, treatment, and adherence reporting for each campaign treatment round
| Category | Round 1 | Round 2 | Round 3 | Round 4 | Total | ||||
|---|---|---|---|---|---|---|---|---|---|
| fMDA | MDA | fMDA | MDA | fMDA | MDA | fMDA | MDA | ||
| Households interviewed, N | 17,704 | 18,237 | 14,610 | 14,584 | 18,004 | 17,528 | 16,050 | 15,257 | 131,975 |
| Individuals listed, N | 95,214 | 90,347 | 79,518 | 70,305 | 88,605 | 90,077 | 81,208 | 79,653 | 674,927 |
| Tested for malaria, n (% listed) | 79,774 (83.8%) | 81,432 (90.1%) | 67,566 (85.0%) | 58,088 (82.6%) | 79,389 (89.6%) | 83,389 (92.6%) | 74,493 (91.7%) | 73,500 (92.3%) | 597,631 (88.5%) |
| Rapid diagnostic test positivity, n (% tested) | 7,866 (9.9%) | 5,790 (7.1%) | 3,797 (5.6%) | 2,213 (3.8%) | 4,509 (5.7%) | 4,186 (5.0%) | 1,475 (2.0%) | 1,073 (1.5%) | 30,898 (5.2%) |
| Eligible for treatment,* N | 26,453 | 89,290 | 17,171 | 69,473 | 14,684 | 88,236 | 6,285 | 72,176 | 383,768 |
| Treated with dihydroartemisinin–piperaquine, n (% eligible) | 25,372 (95.9%) | 78,591 (88.0%) | 17,092 (99.5%) | 56,620 (81.5%) | 14,599 (99.4%) | 72,006 (81.6%) | 8,256 (131.4%) | 64,285 (89.1%) | 336,821 (87.8%) |
| Reporting adherence status, n (% treated) | 13,847 (54.6%) | 36,968 (47.0%) | 7,461 (43.7%) | 17,100 (30.2%) | 8,507 (58.3%) | 48,637 (67.5%) | 5,375 (65.1%) | 43,639 (67.9%) | 181,534 (53.9%) |
| Full adherence, n (% reporting) | 12,676 (91.5%) | 29,800 (80.6%) | 6,843 (91.7%) | 14,467 (84.6%) | 8,134 (95.6%) | 39,197 (80.6%) | 5,016 (93.3%) | 37,054 (84.9%) | 153,197 (84.4%) |
| Partial adherence, n (% reporting) | 903 (6.5%) | 5,974 (16.2%) | 424 (5.7%) | 2,095 (12.3%) | 241 (2.8%) | 7,373 (15.2%) | 288 (5.4%) | 5,141 (11.8%) | 22,438 (12.4%) |
| Nonadherence, n (% reporting) | 267 (1.9%) | 1,194 (3.2%) | 193 (2.6%) | 539 (3.2%) | 134 (1.6%) | 2,067 (4.3%) | 70 (1.3%) | 1,444 (3.3%) | 5,918 (3.3%) |
fMDA = focal MDA; MDA = mass drug administration. Full adherence = all three doses completed; partial adherence = at least one dose, but not all completed; nonadherence = no doses taken.
*
Household participants were eligible for treatment if residing in an area receiving MDA or residing within a household where at least one member tested positive for malaria in an area receiving fMDA.